ZFIN Fish: ak2^hg16/hg16

ZFIN ID: ZDB-FISH-151210-12

ZFIN ID: ZDB-FISH-151210-12

HUMAN DISEASE MODELED by ak2^hg16/hg16

Human Disease	Conditions	Citations
reticular dysgenesis	control	(2)

GENE EXPRESSION
Gene expression in ak2^hg16/hg16

RNA expression

Expressed Gene	Structure	Conditions	Figures
ak2	head intermediate cell mass of mesoderm	control	Fig. 2 from Rissone et al., 2015
atoh1a	posterior lateral line neuromast	control	Fig. 3. from Rissone et al., 2019
gstp1.2	posterior lateral line neuromast	control	Fig. 7. from Rissone et al., 2019
hbae1.1	kidney erythroid lineage cell	control	Fig. 2 from Rissone et al., 2015
hmox1a	hematopoietic system posterior region	control	Fig. 5, Fig. 6 from Rissone et al., 2015
	hematopoietic system posterior region	chemical treatment: N-acetyl-L-cysteine	Fig. 6 from Rissone et al., 2015
mpx	kidney myeloid cell	control	Fig. 2 from Rissone et al., 2015
myb	hematopoietic multipotent progenitor cell hematopoietic stem cell	control	Fig. 4 from Rissone et al., 2015
rag1	(not) thymus	control	Fig. 2 from Rissone et al., 2015

Protein expression No data available

Reporter gene expression No data available

PHENOTYPE
Phenotype in ak2^hg16/hg16

Phenotype	Conditions	Figures
blood island apoptotic process increased process quality, abnormal	control	Fig. 5 from Rissone et al., 2015
granulocyte decreased amount, abnormal	control	Fig. 2 from Rissone et al., 2015
hematopoietic progenitor cell differentiation decreased process quality, abnormal	control	Fig. 4 from Rissone et al., 2015
hematopoietic stem cell differentiation decreased process quality, abnormal	control	Fig. 4 from Rissone et al., 2015
hematopoietic system apoptotic process increased process quality, abnormal	control	Fig. 5 from Rissone et al., 2015
intermediate cell mass of mesoderm apoptotic process increased process quality, abnormal	control	Fig. 5 from Rissone et al., 2015
lymphocyte differentiation decreased process quality, abnormal	control	Fig. 2 from Rissone et al., 2015
myeloid cell development decreased process quality, abnormal	control	Fig. 2 from Rissone et al., 2015
posterior lateral line neuromast gstp1.2 expression decreased amount, abnormal	control	Fig. 7. from Rissone et al., 2019
whole organism decreased life span, abnormal	standard conditions	Fig. 1. from Rissone et al., 2019

CITATIONS (2)